Jane Street’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-130,400
| Closed | -$7.66M | – | 10430 |
|
|
2023
Q4 | $7.66M | Sell |
130,400
-135,400
| -51% | -$7.61M | ﹤0.01% | 2285 |
|
|
2023
Q3 | $11.6M | Buy |
265,800
+257,400
| +3,064% | +$9.19M | ﹤0.01% | 1624 |
|
|
2023
Q2 | $303K | Sell |
8,400
-57,200
| -87% | -$2.36M | ﹤0.01% | 7101 |
|
|
2023
Q1 | $2.44M | Buy |
65,600
+34,500
| +111% | +$1.55M | ﹤0.01% | 3480 |
|
|
2022
Q4 | $1.41M | Sell |
31,100
-16,800
| -35% | -$1.09M | ﹤0.01% | 4432 |
|
|
2022
Q3 | $3.35M | Sell |
47,900
-11,800
| -20% | -$873K | ﹤0.01% | 3281 |
|
|
2022
Q2 | $4.01M | Buy |
59,700
+28,700
| +93% | +$1.83M | ﹤0.01% | 2991 |
|
|
2022
Q1 | $2.55M | Buy |
31,000
+1,900
| +7% | +$194K | ﹤0.01% | 4277 |
|
|
2021
Q4 | $4.27M | Sell |
29,100
-35,400
| -55% | -$5.5M | ﹤0.01% | 3097 |
|
|
2021
Q3 | $11.4M | Buy |
64,500
+12,300
| +24% | +$1.98M | ﹤0.01% | 1638 |
|
|
2021
Q2 | $8.43M | Buy |
52,200
+36,000
| +222% | +$5.78M | ﹤0.01% | 1913 |
|
|
2021
Q1 | $2.77M | Sell |
16,200
-5,100
| -24% | -$1.01M | ﹤0.01% | 3406 |
|
|
2020
Q4 | $4.68M | Sell |
21,300
-44,900
| -68% | -$9.71M | ﹤0.01% | 2221 |
|
|
2020
Q3 | $11M | Buy |
66,200
+42,000
| +174% | +$5.75M | 0.01% | 1145 |
|
|
2020
Q2 | $2.76M | Sell |
24,200
-35,300
| -59% | -$3.42M | ﹤0.01% | 2621 |
|
|
2020
Q1 | $4.57M | Buy |
59,500
+53,800
| +944% | +$4.82M | ﹤0.01% | 1253 |
|
|
2019
Q4 | $735K | Buy |
+5,700
| New | +$550K | ﹤0.01% | 3193 |
|
Other funds holding MRTX
Jane Street's MRTX Position: Q1 2024 in Review
Jane Street sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 409,843 shares — an estimated $24.1M sold.
Jane Street first reported a position in MRTX in Q1 2014 and held it in 22 quarters. The position peaked at $24.1M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Jane Street reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Jane Street sold 409,843 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $24.1M.
- Jane Street first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 22 quarters.
- Jane Street's Mirati Therapeutics, Inc. Common Stock position peaked at $24.1M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Jane Street's 13F filing for Q1 2024, filed 16 May 2024.